‘Every time it’s a battle’: In excruciating pain, sickle cell patients are shunted aside

Amy Mason had toughed it out for hours one day this past July, trying warm soaks and heating pads and deep breathing to soothe pain that felt like her bones were being sawed with a rusty blade. She knew this was a life-threatening emergency of sickle cell disease, in which her misshapen red blood cells […]

Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD)

RIVIERA BEACH, Fla. – November 1st, 2017 Statistically significant results confirm the mechanism of action of Altemia™ for the treatment of SCD Primary and secondary endpoints were met. A clinically meaningful reduction of vaso-occlusive crises (VOCs) was observed in the top line results. No treatment related serious adverse events (SAEs) were observed Majority of patients […]

Micelle BioPharma announces the Successful Completion of a Randomized, Double Blind, and Placebo Controlled Phase of a Clinical Trial in Pediatric Patients with Sickle Cell Disease using Altemia™

RIVIERA BEACH, Fla. – April 2018 Micelle BioPharma today announced the successful completion of a randomized, double blinded, placebo controlled clinical trial in pediatric sickle cell patients aged 5 – 17 years old. The clinical trial is a multi-center study designed to evaluate treatment effects and safety of AltemiaTM, a novel pharmaceutical preparation utilizing the […]

Micelle BioPharma Announces Altemia™ Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Pediatric Patients with Sickle Cell Disease (SCD)

This follows the Orphan Drug Designation for Altemia™ granted by the U.S. Food and Drug Administration (FDA) in 2015 RIVIERA BEACH, Fla. – April 3rd, 2018 Micelle BioPharma today announced that the European Commission has granted Orphan Designation in the European Union (EU) to Altemia, the Company’s novel oral formulation being developed for the treatment […]